Standout Papers

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One <... 2023 2026 202465
  1. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele (2023)
    Jennifer L. Goralski, Jordana E. Hoppe et al. American Journal of Respiratory and Critical Care Medicine

Immediate Impact

5 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

Cystic fibrosis
2024 Standout
Dendritic Polymer‐Based Nanomedicines Remodel the Tumor Stroma: Improve Drug Penetration and Enhance Antitumor Immune Response
2024 Standout
8 intermediate papers

Works of Jonathan H. Rayment being referenced

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Addressing the Role of Cell Adhesion in Tumor Cell Dormancy
2006
and 4 more

Author Peers

Author Last Decade Papers Cites
Jonathan H. Rayment 360 79 144 34 566
Long-Hai Zhao 177 46 61 14 544
Balduin Lucké 192 100 67 16 552
David Mummy 254 28 205 33 526
Rafael Firszt 92 166 121 21 512
J. McRae 205 77 24 27 525
Mohammed Zaki 179 108 76 43 599
Enno Stranzinger 154 183 78 35 482
Julius Renne 303 91 191 33 632
T Heckscher 352 34 51 16 540
S. Ramaiah Ganti 99 178 18 33 566

All Works

Loading papers...

Rankless by CCL
2026